Trastuzumab has an established role for the treatment of HER2-positive early-stage breast cancer. The authors of this review discuss the toxicity associated with trastuzumab and the issues associated with determining its optimum timing and schedule, and assert why this agent should be the standard of care in the adjuvant setting.
- Gabriella Mariani
- Angelica Fasolo
- Luca Gianni